soul trial oral semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an #GLP1RA 14% reduction in MACE with oral among 9,650 people with T2D and established ACC 2025: Oral Semaglutide Reduces

Description

The future of type 1 diabetes care may be less about one treatment, and more about smarter combinations

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and/or chronic kidney disease.

AtPharmaqo Labs UK, we supplyhigh-purity Semaglutide pensdesigned to deliver consistent and reliable results in laboratory and experimental studies

We conducted a ...

Generic Obesity Drugs Hit The Market After Semaglutide Goes Off Patent -Multiple pharma majors launch generic weight-loss drugs on Day 1 -Competition lower than earlier expected -Sharp price disruption visible -Prices at steep discount to Novo Nordisks 8,80016,400/month